Compare · OM vs TMDX
OM vs TMDX
Side-by-side comparison of Outset Medical Inc. (OM) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OM and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $2.56B, about 32.8x OM ($77.9M).
- Over the past year, OM is down 75.8% and TMDX is down 28.6% - TMDX leads by 47.3 points.
- Both names hit the wire about 4 times in the past 4 weeks.
- TMDX has more recent analyst coverage (18 ratings vs 13 for OM).
- Company
- Outset Medical Inc.
- TransMedics Group Inc.
- Price
- $4.23-3.64%
- $74.01-2.55%
- Market cap
- $77.9M
- $2.56B
- 1M return
- -4.51%
- -2.15%
- 1Y return
- -75.81%
- -28.55%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2019
- News (4w)
- 4
- 4
- Recent ratings
- 13
- 18
Outset Medical Inc.
Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It offers Tablo Hemodialysis System, which comprises of a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest OM
- Outset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- General Counsel Brottem John L. was granted 59,830 shares, increasing direct ownership by 198% to 90,107 units (SEC Form 4)
- Chief Financial Officer Gaeta Renee was granted 71,630 shares, increasing direct ownership by 63% to 185,383 units (SEC Form 4)
- Chair and CEO Trigg Leslie was granted 99,160 shares, increasing direct ownership by 100% to 198,034 units (SEC Form 4)
- Outset Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Financial Statements and Exhibits
- Director Hackett Patrick T was granted 10,667 shares, increasing direct ownership by 11% to 105,839 units (SEC Form 4)
- Director Oboyle Kevin C was granted 10,667 shares, increasing direct ownership by 44% to 34,785 units (SEC Form 4)
- Director Prange Karen was granted 10,667 shares, increasing direct ownership by 57% to 29,334 units (SEC Form 4)
- Director Lang Brent D. was granted 10,667 shares, increasing direct ownership by 60% to 28,518 units (SEC Form 4)
- Director Grossman D Keith was granted 10,667 shares, increasing direct ownership by 77% to 24,585 units (SEC Form 4)
Latest TMDX
- Officer Corcoran Nicholas was granted 11,727 shares, increasing direct ownership by 39% to 41,558 units (SEC Form 4)
- Chief Financial Officer Hernandez Gerardo was granted 17,246 shares, increasing direct ownership by 117% to 31,935 units (SEC Form 4)
- President & CEO Hassanein Waleed H was granted 49,669 shares, increasing direct ownership by 41% to 171,093 units (SEC Form 4)
- TransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbH
- Director Gunderson Thomas J. exercised 19,285 shares at a strike of $2.21 and sold $722,377 worth of shares (9,624 units at $75.06), increasing direct ownership by 138% to 16,642 units (SEC Form 4) (for withholding tax)
- SEC Form 144 filed by TransMedics Group Inc.
- SEC Form SD filed by TransMedics Group Inc.
- Director Basile Edward M was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)
- Director Gunderson Thomas J. was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Raines Merilee was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)